Journal
KIDNEY INTERNATIONAL
Volume 84, Issue 3, Pages 433-436Publisher
ELSEVIER SCIENCE INC
DOI: 10.1038/ki.2013.163
Keywords
-
Categories
Ask authors/readers for more resources
Enoxaparin has become the treatment of choice for various thromboembolic diseases. In most patients with end-stage renal disease (ESRD), prophylactic dosage of enoxaparin does not appear to be associated with an increased bleeding risk and can be used without the need for monitoring and adjustment of regimens. Empirical dose adjustment and biological monitoring seem to be necessary along with therapeutic doses. Anti-factor Xa poorly predicts the degree of anticoagulation in ESRD patients given enoxaparin.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available